Enanta Pharma (ENTA) Tops Q2 EPS by 10c, Misses on Revenue

Enanta Pharma (NASDAQ: ENTA) reported Q2 EPS of ($1.06), $0.10 better than the analyst estimate of ($1.16). Revenue for the quarter came in at $14.9 million versus the consensus estimate of $15.95 million.

For earnings history and earnings-related data on Enanta Pharma (ENTA) click here.

You May Also Be Interested In

• Jefferies Group (JEF) PT Lowered to $83 at Oppenheimer
• Bridgeline Digital signs industrial distributor for AI search product
• Yiren Digital Ltd. (YRD) Reports Q1 Loss of RMB5.64